FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2535517419> ?p ?o ?g. }

• W2535517419 abstract "Abstract Abstract 1259 Severe aplastic anemia (SAA) is a life-threatening disorder characterized by pancytopenia and a hypocellular bone marrow. As most patients lack a histocompatible donor, the majority of patients are treated with immunosuppressive therapy (IST) with horse anti-thymocyte globulin plus cyclosporine (h-ATG/CsA). The current limitations of IST in SAA are: 1) most responses are not complete; 2) 1/3 of patients are refractory to initial h-ATG/CsA; 3) hematologic relapses occur in 30–35% of responders following initial response ATG/CsA; 4) and clonal evolution is observed in about 15% of patients at 10 years after first therapy (Scheinberg and Young 2012). Efforts to improve initial IST in treatment-naïve patients with the addition of mycophenolate mofetil and sirolimus to standard h-ATG/CsA or use of lymphocytotoxic agents such as rabbit ATG or alemtuzumab have not yielded better outcomes when compared to standard h-ATG/CsA (Scheinberg and Young 2012). Cyclophosphamide (Cy) has been proposed as an alternative IST regimen to h-ATG/CsA. A pilot and single institution phase II study suggested that high dose Cy (200 mg/kg) yielded similar results to that observed for h-ATG/CsA but with fewer relapses and clonal evolutions (Brodsky, Chen et al. 2010). However, in a randomized study at NHLBI comparing high dose Cy (200 mg/kg) and h-ATG/CsA in treatment-naïve patients excess toxicity and deaths from invasive fungal infections were observed in the Cy arm, which led to the discontinuation of this regimen (Tisdale, Dunn et al. 2000). In a recent Chinese protocol introduced by Dr. Zhang (Institute of Hematology & Blood Disease Hospital, China), lower doses of Cy (30 mg/kg/d * 4 days, 120 mg/kg total) plus CsA, were reported to achieve similar results as with high-dose Cy at 200 mg/kg with reduced toxicity (Kojima, Nakao et al. 2011). Because of the marked improvement in survival in SAA, especially among patients who did not respond to IST, likely due at least in part to improved antifungal drugs (Valdez, Scheinberg et al. 2011), we considered it reasonable to investigate “moderate” dose Cy + CsA as proposed by the Chinese as first line in SAA. The main objective was to assess the safety and efficacy of Cy at 120 mg/kg + low dose CsA, at doses aimed to achieve plasma levels of 100 – 200 mg/L, in treatment-naïve SAA, and the primary hematologic endpoint was response, defined as no longer meeting criteria for SAA, at 6 months. The study was designed to show an increase in complete response rate > 30%, in our experience a surrogate for fewer late events. Prophylactic voriconazole was administered with target levels between 1 – 5.5 ug/L, with ciprofloxacin and Bactrim. From October 2010 to April 2012, 22 patients were accrued. Toxicity from Cy + CsA was considerable and in some cases unexpected, with absolute neutrophil levels of 0/uL universal regardless of pre-therapy blood counts. Granulocyte transfusions were required in 5 participants for uncontrolled infections, and to date 5 patients have died, all from infections. Confirmed fungal infections were documented in 4 participants. In 10 patients with a pre-treatment ANC > 500/uL, 5 remained with severe neutropenia at 6 months as salvage therapies were being sought. In a companion protocol using Cy at 60 mg/kg + fludarabine at 125 mg/m2, neutropenia was also prolonged and severe in a patient leading to pulmonary murcomycosis and need for frequent granulocyte transfusions. In total 9 patients responded to “moderate” dose Cy (120 mg/kg total dose) + CsA, with 4 complete and 5 partial responders. In the relative short follow-up period, cytogenetic abnormalities have been observed in 4 patients: 1 to monosomy 7, 1 del20q, 1 trisomy 15, and 1 del7q. We conclude that Cy at 120 mg/kg + CsA, while capable of producing meaningful hematologic responses in some cases, results in significant toxicity, despite maximum prophylactic and intensive supportive care. The regimen led to very prolonged hospitalizations and frequent bacterial and fungal infections. Hematologic relapses with a higher than expected number of clonal evolution events were observed in our cohort. Due to the high toxicity of Cy (120 mg/kg) + CsA, without likelihood of benefit from decreased relapse and clonal evolution, both protocols using “moderate” dose Cy were terminated by our data and safety monitoring board. Although Cy has activity in SAA, its toxicity is not justified when far less toxic alternatives, such as h-ATG, are available. Disclosures: Off Label Use: Cyclophosphamide in aplastic anemia." @default.
• W2535517419 created "2016-10-28" @default.
• W2535517419 creator A5015491576 @default.
• W2535517419 creator A5020688388 @default.
• W2535517419 creator A5026597677 @default.
• W2535517419 creator A5049066393 @default.
• W2535517419 creator A5072063614 @default.
• W2535517419 creator A5074515375 @default.
• W2535517419 creator A5076074380 @default.
• W2535517419 creator A5078240953 @default.
• W2535517419 creator A5079533727 @default.
• W2535517419 creator A5080201916 @default.
• W2535517419 creator A5081398715 @default.
• W2535517419 date "2012-11-16" @default.
• W2535517419 modified "2023-09-28" @default.
• W2535517419 title "Even “Moderate” Dose Cyclophosphamide for Severe Aplastic Anemia Is Associated with Significant Toxicities and Does Not Prevent Relapse and Clonal Evolution" @default.
• W2535517419 doi "https://doi.org/10.1182/blood.v120.21.1259.1259" @default.
• W2535517419 hasPublicationYear "2012" @default.
• W2535517419 type Work @default.
• W2535517419 sameAs 2535517419 @default.
• W2535517419 citedByCount "1" @default.
• W2535517419 countsByYear W25355174192016 @default.
• W2535517419 crossrefType "journal-article" @default.
• W2535517419 hasAuthorship W2535517419A5015491576 @default.
• W2535517419 hasAuthorship W2535517419A5020688388 @default.
• W2535517419 hasAuthorship W2535517419A5026597677 @default.
• W2535517419 hasAuthorship W2535517419A5049066393 @default.
• W2535517419 hasAuthorship W2535517419A5072063614 @default.
• W2535517419 hasAuthorship W2535517419A5074515375 @default.
• W2535517419 hasAuthorship W2535517419A5076074380 @default.
• W2535517419 hasAuthorship W2535517419A5078240953 @default.
• W2535517419 hasAuthorship W2535517419A5079533727 @default.
• W2535517419 hasAuthorship W2535517419A5080201916 @default.
• W2535517419 hasAuthorship W2535517419A5081398715 @default.
• W2535517419 hasConcept C126322002 @default.
• W2535517419 hasConcept C203014093 @default.
• W2535517419 hasConcept C2776694085 @default.
• W2535517419 hasConcept C2776755627 @default.
• W2535517419 hasConcept C2777063308 @default.
• W2535517419 hasConcept C2778715236 @default.
• W2535517419 hasConcept C2779015954 @default.
• W2535517419 hasConcept C2780007613 @default.
• W2535517419 hasConcept C2780882860 @default.
• W2535517419 hasConcept C2781413609 @default.
• W2535517419 hasConcept C2781440808 @default.
• W2535517419 hasConcept C2911091166 @default.
• W2535517419 hasConcept C29730261 @default.
• W2535517419 hasConcept C71924100 @default.
• W2535517419 hasConcept C90924648 @default.
• W2535517419 hasConceptScore W2535517419C126322002 @default.
• W2535517419 hasConceptScore W2535517419C203014093 @default.
• W2535517419 hasConceptScore W2535517419C2776694085 @default.
• W2535517419 hasConceptScore W2535517419C2776755627 @default.
• W2535517419 hasConceptScore W2535517419C2777063308 @default.
• W2535517419 hasConceptScore W2535517419C2778715236 @default.
• W2535517419 hasConceptScore W2535517419C2779015954 @default.
• W2535517419 hasConceptScore W2535517419C2780007613 @default.
• W2535517419 hasConceptScore W2535517419C2780882860 @default.
• W2535517419 hasConceptScore W2535517419C2781413609 @default.
• W2535517419 hasConceptScore W2535517419C2781440808 @default.
• W2535517419 hasConceptScore W2535517419C2911091166 @default.
• W2535517419 hasConceptScore W2535517419C29730261 @default.
• W2535517419 hasConceptScore W2535517419C71924100 @default.
• W2535517419 hasConceptScore W2535517419C90924648 @default.
• W2535517419 hasLocation W25355174191 @default.
• W2535517419 hasOpenAccess W2535517419 @default.
• W2535517419 hasPrimaryLocation W25355174191 @default.
• W2535517419 hasRelatedWork W1976732671 @default.
• W2535517419 hasRelatedWork W2000929442 @default.
• W2535517419 hasRelatedWork W2011572042 @default.
• W2535517419 hasRelatedWork W2014549308 @default.
• W2535517419 hasRelatedWork W2066484486 @default.
• W2535517419 hasRelatedWork W2082980816 @default.
• W2535517419 hasRelatedWork W2084968573 @default.
• W2535517419 hasRelatedWork W2276099755 @default.
• W2535517419 hasRelatedWork W2348125190 @default.
• W2535517419 hasRelatedWork W2422516190 @default.
• W2535517419 hasRelatedWork W2534309997 @default.
• W2535517419 hasRelatedWork W2567211804 @default.
• W2535517419 hasRelatedWork W2572354051 @default.
• W2535517419 hasRelatedWork W2653911491 @default.
• W2535517419 hasRelatedWork W2956457819 @default.
• W2535517419 hasRelatedWork W2979406877 @default.
• W2535517419 hasRelatedWork W2979973719 @default.
• W2535517419 hasRelatedWork W3113281485 @default.
• W2535517419 hasRelatedWork W3199076861 @default.
• W2535517419 hasRelatedWork W69891408 @default.
• W2535517419 isParatext "false" @default.
• W2535517419 isRetracted "false" @default.
• W2535517419 magId "2535517419" @default.
• W2535517419 workType "article" @default.